What was JOHNSON & JOHNSON's revenue in Q2 2026?

JOHNSON & JOHNSON reported revenue of $25.3B (+6.6% year-over-year) for Q2 2026.

What was JOHNSON & JOHNSON's EPS in Q2 2026?

JOHNSON & JOHNSON reported diluted EPS of $2.27 for Q2 2026.

What is JOHNSON & JOHNSON's guidance for fy_current?

JOHNSON & JOHNSON provided fy_current guidance of $101.1B to $101.1B.

JOHNSON & JOHNSON (JNJ) Earnings - Revenue, EPS & Net Income

8 quarters held7/8 transcripts analyzed1/40 figures attestedNext: Sep 9, 2026, 11:00 AM · webcast

Connect your agent

PeriodRevenueYoYNet incomeEPS (dil.)Filed

Q2 2026$25.3B+6.6%$5.5B$2.27Jul 16, 2026

LATESTEarnings filing (8-K)10-QFiled Jul 15, 2026, 7:49 AM ET

Earnings call · Jul 15, 2026deck deck webcast

	Q2 FY26	YoY	6M FY26
Revenue	$25.3B¹	+6.6%	$49.4B
Net income	$5.5B	-0.1%	$10.8B
Op income	$6.7B	–	–
EPS (dil.)	$2.27	–	$4.41
EPS (basic)	–	–	–
Gross margin	68.2%	+0.3pp
Op margin	26.7%	–
Net margin	21.9%	-1.4pp

[1] “Sales to customers $ 25,310 100.0 $ 23,743 100.0 6.6” view source

Guidance & outlook

Management guidance

Q2 2026

fy_current

revenue

$101.1B—$101.1B

eps_diluted

$11.68—$11.68

eps_diluted

$11.58—$11.58

Q1 2026$24.1B+9.9%$5.2B$2.14Apr 14, 2026

Earnings filing (8-K)10-QFiled Apr 14, 2026, 7:35 AM ET

Earnings call · Apr 14, 2026transcript View original prepared remarks Q&A deck webcast

	Q1 FY26	YoY
Revenue	$24.1B	+9.9%
Net income	$5.2B	-52.4%
Op income	$6.0B	-56.1%
EPS (dil.)	$2.14	-52.9%
EPS (basic)	–	–
Gross margin	66.3%	-0.1pp
Op margin	24.9%	-37.4pp
Net margin	21.8%	-28.4pp

Q4 2025$24.6B+9.1%$5.1B$2.10Jan 21, 2026

Earnings filing (8-K)10-KFiled Jan 21, 2026, 7:46 AM ET

Earnings call · Jan 21, 2026transcript View original prepared remarks Q&A deck webcast

	Q4 FY25	YoY	FY25
Revenue	$24.6B	+9.1%	$94.2B
Net income	$5.1B	+49.1%	$26.8B
Op income	–	–	–
EPS (dil.)	$2.10	+48.9%	$11.03
EPS (basic)	–	–	–

Q3 2025$24.0B+6.8%$5.2B$2.12Oct 14, 2025

Earnings filing (8-K)10-QFiled Oct 14, 2025, 7:22 AM ET

Earnings call · Oct 14, 2025transcript View original prepared remarks Q&A deck webcast

	Q3 FY25	YoY
Revenue	$24.0B	+6.8%
Net income	$5.2B	+91.2%
Op income	–	–
EPS (dil.)	$2.12	+91.0%
EPS (basic)	–	–

Q2 2025$23.7B+5.8%$5.5B$2.29Jul 16, 2025

Earnings filing (8-K)10-QFiled Jul 16, 2025, 8:06 AM ET

Earnings call · Jul 16, 2025transcript View original prepared remarks Q&A deck webcast

	Q2 FY25	YoY	6M FY25
Revenue	$23.7B	+5.8%	$93.4B
Net income	$5.5B	+18.2%	–
Op income	–	–	–
EPS (dil.)	$2.29	+18.7%	$10.85
EPS (basic)	–	–	–

Q1 2025$21.9B+2.4%$11.0B$4.54Apr 15, 2025

Earnings filing (8-K)10-QFiled Apr 15, 2025, 8:14 AM ET

Earnings call · Apr 15, 2025transcript View original prepared remarks Q&A deck webcast

	Q1 FY25	YoY
Revenue	$21.9B	+2.4%
Net income	$11.0B	+237.9%
Op income	–	–
EPS (dil.)	$4.54	+238.8%
EPS (basic)	–	–

Q4 2024$22.5B+5.3%$3.4B$1.41Jan 22, 2025

Earnings filing (8-K)10-KFiled Jan 22, 2025, 6:35 AM ET

Earnings call · Jan 22, 2025transcript View original prepared remarks Q&A deck webcast

	Q4 FY24	YoY	FY24
Revenue	$22.5B	+5.3%	$88.8B
Net income	$3.4B	-17.0%	$14.1B
Op income	–	–	–
EPS (dil.)	$1.41	-17.1%	$5.79
EPS (basic)	–	–	–

Q3 2024$22.5B+5.2%$2.7B$1.11Oct 15, 2024

Earnings filing (8-K)10-QFiled Oct 15, 2024, 7:37 AM ET

Earnings call · Oct 15, 2024transcript View original prepared remarks Q&A deck webcast

	Q3 FY24	YoY
Revenue	$22.5B	+5.2%
Net income	$2.7B	-37.5%
Op income	–	–
EPS (dil.)	$1.11	-34.3%
EPS (basic)	–	–
Net margin	12.0%	-8.2pp

IR event calendar

Upcoming

Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare ConferenceSep 9, 2026, 11:00 AM
webcast press_release webcast
Morgan Stanley 24th Annual Global Healthcare ConferenceSep 14, 2026, 11:30 AM
press_release

Past

Johnson and Johnson OTTAVA Investor CallAug 3, 2026, 8:00 AM
webcast press_release transcript webcast
SRS ConferenceJul 22, 2026
webcast
Johnson & Johnson Second Quarter 2026 Earnings CallJul 15, 2026, 8:30 AM
webcast document presentation press_release transcript webcast
Johnson & Johnson to Participate in the Goldman Sachs 47 th Annual Global Healthcare ConferenceJun 9, 2026, 10:00 AM
webcast press_release transcript webcast
Johnson & Johnson to Participate in the Bernstein’s 42nd Annual Strategic Decisions ConferenceMay 27, 2026, 11:00 AM
webcast press_release transcript webcast
Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare ConferenceMay 19, 2026, 11:30 AM
webcast press_release transcript webcast

+62 more

IR event calendar last checked 2026-08-16 19:00:15+00; events announced since are not shown.

Filing coverage

63 filings indexed · 94,973 XBRL facts

Filing	Date	Period	Sections	Tables
8-K	2026-08-04	–	3	0
8-K	2026-07-29	–	1	0
8-K	2026-07-28	–	1	0
10-Q	2026-07-23	–	29	123
8-K	2026-07-15	Q2 2026	9	0
8-K	2026-04-28	–	1	0
10-Q	2026-04-22	–	30	67
8-K	2026-04-14	Q1 2026	9	0
10-K	2026-02-11	–	57	97
8-K	2026-01-21	Q4 2025	7	0

Showing the latest 10 of 63 — the full set is in the API.

Related Research

Analysis

Guidance & outlook

Management guidance

fy_current

Filing coverage

Related Research

The $15 Billion Earnings Illusion Behind AbbVie's 96x P/E

Related Research

The $15 Billion Earnings Illusion Behind AbbVie's 96x P/E

JOHNSON & JOHNSON (JNJ) Earnings History

Guidance & outlook

Management guidance

fy_current

Filing coverage

Related Research

The $15 Billion Earnings Illusion Behind AbbVie's 96x P/E

Related Research

The $15 Billion Earnings Illusion Behind AbbVie's 96x P/E